MedTech Acquisition raises additional $22.3M in PIPE for TriSalus merger; amends merger agreement

TriSalus Life Sciences, Inc.

Entered into subscription agreements for 2,229,500 shares of Series A Preferred at $10/share, aggregate $22,295,000.
Combined with prior $17.855M, total PIPE proceeds of approximately $40.15M.
Backstop Letter Agreement with Sponsor terminated as $2M commitment fulfilled by members via additional subscriptions.
Third Amendment to Merger Agreement updates form of bylaws for post-merger TriSalus Life Sciences.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.